Reykjavík, March 28, 2025 (GLOBE NEWSWIRE) — (“Amaroq” or the “Company“) 2024 Full Year Financial Results 2024 – a pivotal year marking the transition from developer to producer at our flagship Nalunaq mine TORONTO, ONTARIO – 28 March 2025 – Amaroq Minerals Ltd. (AIM, TSX-V, NASDAQ Iceland: AMRQ), an independent mining company with a substantial
CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the full year of 2024. Recent Highlights: 2024 Revenue from Continuing Operations of $20.2 million grew 181% year-over-year, from $7.2 million last year. Operating loss for continuing operations was $0.1 million, compared to 11.7
Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity with 12-week data expected 4Q25 Cash, cash equivalents and marketable securities of $358 million, expected to
HUNTSVILLE, Ala. (WAFF) – As market volatility dominates headlines, many investors feel pressure to track daily market movements and compare their portfolios to major indexes like the S&P 500. However, financial expert Marshall Clay with The Welch Group warns that this mindset can lead to unnecessary risks and short-term thinking. The Illusion of Diversification “It’s
Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months Leveraged hemophilia A albumin platform to achieve in vivo proof-of-concept in multiple secreted protein deficiencies to support wholly-owned follow-on program Progressed four Wave 1 Ionis targets to
HOUSTON, March 13, 2025 (GLOBE NEWSWIRE) — U.S. Energy Corporation (NASDAQ: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in operating a portfolio of high-quality producing assets, today reported financial and operating results for the fourth quarter and year ended December 31, 2024. FULL YEAR 2024 HIGHLIGHTS Continued the divestment of legacy
– Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases – Lead target and indication to be announced MY 2025 – Cash balance of $185.2 million expected to fund operations into 2H 2027 Get the latest news delivered to your inbox Sign up for The Manila Times
– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations –
OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) — ContextLogic Inc. (Nasdaq: LOGC) (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter and fiscal year ended December 31, 2024. Company Update During 2024, management took several significant steps in the evolution of the Company’s business. These included, first, the sale of
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL) Presented positive initial data from Phase 1 multi-center clinical trial of IMPT-314 in patients with aggressive LBCL in the 3rd line and later setting at the